imatinib mesylate has been researched along with Neutropenia in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (43.48) | 29.6817 |
| 2010's | 22 (47.83) | 24.3611 |
| 2020's | 4 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bett, Y; Ezzi, M; McLigeyo, A; Mwanzi, S; Odhiambo, A; Ong'ondi, M; Othieno-Abinya, N; Oyiro, P; Rajab, J | 1 |
| Choi, SY; Jung, SY; Kee, KM; Kim, DW; Kim, SH; Lee, JI; Noh, H; Shin, H; Yang, SY; Zang, DY | 1 |
| Doi, S; Hamada, T; Kato, K; Kishimoto, W; Moriguchi, T; Tashiro, Y; Ueda, C; Yoshinaga, N | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Cho, H; Doki, Y; Hahn, S; Hirota, S; Honda, H; Im, SA; Ishikawa, T; Kang, YK; Kong, SH; Kurokawa, Y; Kwon, OK; Lee, HJ; Lee, KH; Masuzawa, T; Matsumoto, S; Nabeshima, K; Nishida, T; Park, SR; Ryu, MH; Shimokawa, T; Yang, HK; Yook, JH | 1 |
| Bunworasate, U; Caguioa, PB; Choi, CW; Chung, JS; Comia, NS; Do, YR; Jootar, S; Jung, CW; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kong, JH; Kwak, JY; Lee, SE; Lee, WS; Mun, YC; Oh, SJ; Park, J; Park, JS; Reksodiputro, AH; Shin, HJ; Zang, DY | 1 |
| Gupta, B; Kumar, A; Pant, G; Pooniya, V; Sharma, A; Verma, N | 1 |
| Kang, HH; Kim, IK; Kim, JW; Lee, DG; Lee, SH; Rhee, CK; Yeo, CD | 1 |
| Abdelaal, M; Abrar, MB; Absi, A; Al-Amri, A; Alsaeed, A; Alshehri, MA; Alsobhi, E; Alzahrani, Z; Bayashoot, S; El-Hemaidi, I; Hashem, H; Merdad, A; Radi, S; Shiekhi, H; Warsi, A | 1 |
| Bosma, JW; Farag, S; Gelderblom, H; Kerst, JM; Sleijfer, S; Steeghs, N; Verschoor, AJ | 1 |
| Gao, XN; Guo, YL; Han, XP; Jin, XS; Jing, Y; Liu, K; Yao, ZL; Yu, L; Zhang, R | 1 |
| Hwang, YY; Kwong, YL; So, JC; Tse, E; Wan, TS | 1 |
| Calbacho, M; Cervantes, F; Colomer, D; González, M; Hernández-Boluda, JC; Jonte, F; López-Garrido, P; Martínez, J; Montero, MI; Nieto, JB; Pereira, A; Pérez-López, C; Pérez-Rus, G; Román-Gómez, J; Sureda, A | 1 |
| Etienne, G; Milpied, B; Nicolini, FE; Réa, D; Rigal-Huguet, F; Tulliez, M | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Shim, HJ; Yoon, JY | 1 |
| Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Medhi, K; Raina, V; Sharma, A | 1 |
| Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR | 1 |
| Allard, C; Berger, M; Berthou, C; Coiteux, V; Corm, S; Delmer, A; Eclache, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Jourdan, E; Legros, L; Mahon, FX; Maloisel, F; Nicolini, FE; Preudhomme, C; Rea, D; Rigal-Huguet, F; Roche-Lestienne, C; Rousselot, P; Vekhoff, A | 1 |
| Bang, SM; Cheong, JW; Chung, JS; Eom, KS; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, DH; Kim, H; Kim, HJ; Kim, MK; Kim, YK; Lee, HG; Min, YH; Moon, JH; Oh, SJ; Park, EK; Park, J; Park, JS; Park, MR; Park, SY; Ryoo, HM; Sohn, SK; Won, JH; Yoon, SS; Zang, DY | 1 |
| Amagasaki, T; Fukuda, T; Kanda, Y; Kurokawa, M; Maeda, Y; Matsuda, A; Nagai, T; Nakamae, H; Nakaseko, C; Ohnishi, K; Shibayama, H; Yanada, M | 1 |
| Hino, M; Koh, KR; Nakamae, H; Nakane, T; Nakao, T; Terada, Y; Yamane, T; Yoshida, N | 1 |
| Huang, H; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Zhao, Y | 1 |
| Li, QW; Lu, JY; Sun, JZ; Wang, RL; Xiao, WH; Zhu, JH | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Abraham, LJ; Appaji, L; Arunakumari, BS; Bhise, R; Govindbabu, K; Lakshmaiah, KC; Lokanatha, D; Purohit, S; Suresh, TM | 1 |
| Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S | 1 |
| Arias-Pulido, H; Bauman, JE; Carr, LL; Cerilli, LA; Eaton, KD; Jones, DV; Lee, SJ; Martins, RG; Wallace, SG | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Marin, D; Marktel, S | 1 |
| Campbell, L; Grigg, A; Hoyt, R; Juneja, S; Lynch, K; McNamara, C; Roberts, A; Szer, J | 1 |
| Ebnöther, M; Gratwohl, A; Heim, D; Linn, M; Meyer-Monard, S; Tichelli, A; Tsakiris, D | 1 |
| Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M | 1 |
| Carrasco, M; Conde, E; de Miguel, M; Díaz-Mediavilla, J; Martínez, JA; Sanz, MA; Sierra, J; Sureda, A | 1 |
| Bekele, BN; Cortes, JE; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Sneed, TB; Talpaz, M; Wierda, W; Zhou, X | 1 |
| Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Quintas-Cardama, A; Rios, MB; Talpaz, M | 1 |
| Higashi, T; Iwashige, A; Kato, C; Machida, S; Mizobe, T; Morimoto, H; Ogawa, R; Tanaka, Y; Toda, Y; Tsukada, J | 1 |
| Copland, M; Holyoake, TL; Jørgensen, HG | 1 |
| Asaka, M; Dazai, M; Hashino, S; Imamura, M; Izumiyama, K; Kobayashi, S; Kondo, T; Morita, R; Onozawa, M; Ota, S; Sogabe, S | 1 |
| Goto, T; Igaki, N; Kanda, S; Matsuda, T; Ohyama, M; Takashima, M; Tamada, F | 1 |
| Calbecka, M; Hellmann, A; Prejzner, W; Wyrowinska, E; Zaucha, JM | 1 |
| Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M | 1 |
| Colson, YL; Marty, FM; Paul, S | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kondo, K; Matsuno, K; Mori, A; Musashi, M; Onozawa, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N | 1 |
| Arthur, C; Branford, S; Filshie, R; Hughes, T; Koelmeyer, R; Lynch, K; Milner, A; Moreton, S; Schwarer, A; Taylor, K | 1 |
| Baccarani, M; Cortes, J; Deininger, MW; Druker, BJ; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Kantarjian, H; Niederwieser, D; Paquette, R; Park, B; Smith, D; So, C; Stone, R | 1 |
| Choi, CW; Choi, IK; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Park, SJ; Seo, HY; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B | 1 |
19 trial(s) available for imatinib mesylate and Neutropenia
| Article | Year |
|---|---|
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Eruptions; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organ Sparing Treatments; Republic of Korea; Stomach Neoplasms; Tumor Burden | 2017 |
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Topics: Adult; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thrombocytopenia; Treatment Outcome | 2017 |
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Spain; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2010 |
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; Remission Induction; RNA, Neoplasm; Stem Cells; Survival Analysis; Thrombocytopenia; Transcription, Genetic; Treatment Outcome | 2010 |
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Logistic Models; Male; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thrombocytopenia; Time Factors; Transcription, Genetic; Treatment Outcome; Young Adult | 2011 |
Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Topics: Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Benzamides; Benzylisoquinolines; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome | 2012 |
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Frail Elderly; Humans; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2012 |
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Count; Cytogenetic Analysis; Drug Resistance; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Reticulin; Thrombocytopenia; Treatment Outcome | 2003 |
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia | 2003 |
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Patient Dropouts; Piperazines; Prospective Studies; Pyrimidines; Time Factors; Transcription, Genetic; Treatment Outcome | 2007 |
27 other study(ies) available for imatinib mesylate and Neutropenia
| Article | Year |
|---|---|
Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2022 |
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Body Weight; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Precision Medicine; Safety; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2020 |
[BCR-ABL1-positive myelodysplastic syndrome with neutropenia and anemia treated successfully with imatinib mesylate].
Topics: Aged, 80 and over; Anemia; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Myelodysplastic Syndromes; Neutropenia; Protein Kinase Inhibitors | 2020 |
Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience.
Topics: Bone Marrow Examination; Central Nervous System Neoplasms; Child; Female; Humans; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukocyte Count; Male; Neutropenia; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery.
Topics: Acute Lung Injury; Animals; Benzamides; Disease Models, Animal; Female; Imatinib Mesylate; Lipopolysaccharides; Mice; Mice, Inbred ICR; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Recovery of Function; Treatment Outcome | 2013 |
Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Retrospective Studies; Saudi Arabia; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Neutropenia; Proto-Oncogene Mas | 2015 |
[Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Vindesine | 2015 |
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Topics: Benzamides; Biopsy, Needle; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; Erythropoietin; Fertility; Food-Drug Interactions; France; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Diseases; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2010 |
Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.
Topics: Aged; Antineoplastic Agents; Benzamides; Exanthema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neutropenia; Piperazines; Prognosis; Pyrimidines; Tomography, X-Ray Computed | 2010 |
[Chronic myelogenous leukemia complicated by drug-induced agranulocytosis].
Topics: Aged; Agranulocytosis; Benzamides; Butylscopolammonium Bromide; Colonoscopy; Female; Flumazenil; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Premedication; Pyrimidines; Treatment Outcome | 2011 |
[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Edema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Skin Neoplasms; Survival Rate; Vomiting | 2011 |
Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate.
Topics: Adolescent; Anemia; Antineoplastic Agents; Benzamides; Child; Exanthema; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nausea; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Benzamides; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Thrombocytopenia | 2003 |
G-CSF for imatinib-induced neutropenia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines | 2003 |
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Topics: Adult; Aged; Benzamides; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Neutropenia; Pilot Projects; Piperazines; Pyrimidines; Recombinant Proteins | 2004 |
Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Chromosome Aberrations; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Remission Induction; RNA, Messenger | 2004 |
Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Neutropenia; Piperazines; Pyrimidines; Reproducibility of Results | 2005 |
[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Topics: Bacterial Infections; Benzamides; Blast Crisis; Drug Therapy, Combination; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction | 2004 |
Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.
Topics: Administration, Oral; Antineoplastic Agents; Antitubercular Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Laparotomy; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2005 |
Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Recombinant Proteins | 2006 |
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Bone Marrow Transplantation; Cefepime; Cephalosporins; Combined Modality Therapy; Cunninghamella; Daunorubicin; Drug Resistance, Multiple, Fungal; Female; Humans; Imatinib Mesylate; Immunocompromised Host; Lung Diseases, Fungal; Middle Aged; Neutropenia; Piperazines; Pneumonectomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Transplantation Conditioning; Triazoles; Vancomycin; Vincristine; Voriconazole; Zygomycosis | 2006 |
Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Proliferation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Leukemic; Genes, abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Pyrimidines | 2006 |
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Chromosome Aberrations; Chronic Disease; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Logistic Models; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Piperazines; Prognosis; Pyrimidines; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2007 |
Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Dose-Response Relationship, Drug; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thrombocytopenia | 2007 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Enzyme Inhibitors; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Immunosuppression Therapy; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Transfusion; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous | 2001 |